Herein, we report a de novo chemical design of supramolecular polymer materials (SPMs-1-3) by condensation polymerization, consisting of (i) soft polymeric chains (polytetramethylene glycol and tetraethylene glycol) and (ii) strong and reversible quadruple H-bonding cross-linkers (from 0 to 30 mol %). The former contributes to the formation of the soft domain of the SPMs, and the latter furnishes the SPMs with desirable mechanical properties, thereby producing soft, stretchable, yet tough elastomers. The resulting SPM-2 was observed to be highly stretchable (up to 17 000% strain), tough (fracture energy ∼30 000 J/m), and self-healing, which are highly desirable properties and are superior to previously reported elastomers and tough hydrogels. Furthermore, a gold, thin film electrode deposited on this SPM substrate retains its conductivity and combines high stretchability (∼400%), fracture/notch insensitivity, self-healing, and good interfacial adhesion with the gold film. Again, these properties are all highly complementary to commonly used polydimethylsiloxane-based thin film metal electrodes. Last, we proceed to demonstrate the practical utility of our fabricated electrode via both in vivo and in vitro measurements of electromyography signals. This fundamental understanding obtained from the investigation of these SPMs will facilitate the progress of intelligent soft materials and flexible electronics.
The lack of persistence of transferred autologous mature lymphocytes in humans has been a major limitation to the application of effective cell transfer therapies. The results of a pilot clinical trial in 13 patients with metastatic melanoma suggested that conditioning with nonmyeloablative chemotherapy before adoptive transfer of activated tumor-reactive T cells enhances tumor regression and increases the overall rates of objective clinical responses. The present report examines the relationship between T cell persistence and tumor regression through analysis of the TCR β-chain V region gene products expressed in samples obtained from 25 patients treated with this protocol. Sequence analysis demonstrated that there was a significant correlation between tumor regression and the degree of persistence in peripheral blood of adoptively transferred T cell clones, suggesting that inadequate T cell persistence may represent a major factor limiting responses to adoptive immunotherapy.
Cluster of differentiation (CD)8 ؉ T cells exist as naive, central memory, and effector memory subsets, and any of these populations can be genetically engineered into tumor-reactive effector cells for adoptive immunotherapy. However, the optimal subset from which to derive effector CD8 ؉ T cells for patient treatments is controversial and understudied. We investigated human CD8 ؉ T cells and found that naive cells were not only the most abundant subset but also the population most capable of in vitro expansion and T-cell receptor transgene expression. Despite increased expansion, naive-derived cells displayed minimal effector differentiation, a quality associated with greater efficacy after cell infusion. Similarly, the markers of terminal differentiation, killer cell lectin-like receptor G1 and CD57, were expressed at lower levels in cells of naive origin. Finally, naive-derived effector cells expressed higher CD27 and retained longer telomeres, characteristics that suggest greater proliferative potential and that have been linked to greater efficacy in clinical trials. Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy. (Blood. 2011;117(3):808-814) IntroductionIt is now possible to genetically engineer human T lymphocytes to express virtually any known gene, including genes encoding T-cell receptors (TCRs) or chimeric antigen receptors (CARs), to provide the desired T-cell specificity. These gene-engineered lymphocytes hold the promise to treat infectious diseases and cancer, 1-10 but the appropriate substrate cells to use is understudied, and most current protocols simply transfer genes into "bulk" peripheral blood mononuclear cells (PBMCs). Varieties of data indicate that T cells, and in particular CD8 ϩ T cells, are worthy substrates for gene engineering. However, CD8 ϩ T cells in peripheral blood are themselves a complex mixture, composed of at least 3 major subsets-naive (T N ), central memory (T CM ), and effector memory (T EM )-each having different functional qualities.The optimal subset to engineer for adoptive immunotherapy is controversial. 8,[11][12][13][14] Memory CD8 ϩ T-cell subsets are more studied than naive cells, because antigen-specific clones can be found at increased frequencies. In a landmark paper, Berger et al 13 have shown in macaques that effector cells derived from T CM rather than T EM possess greater ability to survive and establish immunologic memory after infusion. This finding is consistent with data comparing memory subsets in mice. 15 However, T N cells were not explicitly analyzed in these reports, 12 an omission that might be important given recent findings in mice that naive T cells convey more antitumor activity than memory cells. 12 Short of conducting a series of clinical trials, the decision of which CD8 ϩ T-cell subset to use for clinical protocols will depend on the cell phenotypes that result from transduction of T...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.